Adverse drug reactions: a cohort study in internal medicine units at a university hospital

被引:60
作者
Camargo, AL
Ferreira, MBC
Heineck, I
机构
[1] Univ Fed Rio Grande do Sul, CIM RS Ctr Informacoes Medicamentos Rio Grande Su, BR-90610000 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, ICBS, Dept Pharmacol, BR-90046900 Porto Alegre, RS, Brazil
[3] Univ Fed Rio Grande do Sul, Fac Pharm, Dept Medicat Prod & Control, BR-90610000 Porto Alegre, RS, Brazil
关键词
adverse drug reactions; pharmacological surveillance; intensive monitoring; hospitalized patients;
D O I
10.1007/s00228-005-0086-7
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Objectives: Adverse drug reactions (ADRs) are important causes of hospitalization, morbidity and mortality in hospitalized patients. In addition to the impact they have on human life, they also significantly influence health costs. This study intended to (1) identify suspected ADRs and establish their frequency of development, (2) establish a causal relationship with the suspected drug(s) and (3) verify if there is an association between the development of an ADR and factors such as age, gender, number of diagnoses and number of prescribed medications. Methods: This cohort study considered hospitalized patients at five inpatient internal medicine units in a university hospital located in southern Brazil. Patients were intensively monitored in order to identify suspected ADRs during hospitalization. The types of reactions were classified and a causal relationship was established using an algorithm. Results: The cohort study followed 333 patients and approximately 43% of them presented at least one suspected ADR. Three hundred and sixty suspected ADRs were identified, with 19.7% manifesting before the patient was admitted and 80.3% during hospitalization. Medications that were most commonly involved in these suspected cases were anti-infectious agents followed by drugs that act on the central nervous system (CNS). The follow-up length and number of medications in use were independent risk factors for the development of an ADR. The same relationship was not observed for age, gender and number of diagnoses. Conclusion: ADRs are a major problem in our setting and measures must be adopted to minimize them.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 25 条
[1]
[Anonymous], ADVERSE DRUG REACTIO
[2]
[Anonymous], 2002, Safety of Medicines - A Guide to Detecting and Reporting Adverse Drug Reactions - Why Health Professionals Need to Take Action
[3]
Computerized surveillance of adverse drug reactions in hospital: pilot study [J].
Azaz-Livshits, T ;
Levy, M ;
Sadan, B ;
Shalit, M ;
Geisslinger, G ;
Brune, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (03) :309-314
[4]
Patient risk factors for adverse drug events in hospitalized patients [J].
Bates, DW ;
Miller, EB ;
Cullen, DJ ;
Burdick, L ;
Williams, L ;
Laird, N ;
Petersen, LA ;
Small, SD ;
Sweitzer, BJ ;
Vander Vliet, M ;
Leape, LL .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (21) :2553-2560
[5]
Begaud B, 2002, BR J CLIN PHARM, V54, P548
[6]
SENSITIVITY AND SPECIFICITY OF 3 METHODS OF DETECTING ADVERSE DRUG-REACTIONS [J].
BERRY, LL ;
SEGAL, R ;
SHERRIN, TP ;
FUDGE, KA .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1988, 45 (07) :1534-1539
[7]
Analysis of the direct cost of adverse drug reactions in hospitalised patients [J].
Bordet, R ;
Gautier, S ;
Le Louet, H ;
Dupuis, B ;
Caron, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 56 (12) :935-941
[8]
Undocumented patient information: An impediment to quality of care [J].
Cox, JL ;
Zitner, D ;
Courtney, KD ;
MacDonald, DL ;
Paterson, G ;
Cochrane, B ;
Mathers, J ;
Merry, H ;
Flowerdew, G ;
Johnstone, DE .
AMERICAN JOURNAL OF MEDICINE, 2003, 114 (03) :211-216
[9]
Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine [J].
Fattinger, K ;
Roos, M ;
Vergères, P ;
Holenstein, C ;
Kind, B ;
Masche, U ;
Stocker, DN ;
Braunschweig, S ;
Kullak-Ublick, GA ;
Galeazzi, RL ;
Follath, F ;
Gasser, T ;
Meier, PJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (02) :158-167
[10]
Heineck I., 1999, HOSP PHARM, V34, P946